Drug Discovery for Kinetoplastid Diseases: Future Directions.
| Title: | Drug Discovery for Kinetoplastid Diseases: Future Directions. |
|---|---|
| Authors: | Rao SPS; Novartis Institute for Tropical Diseases (NITD) , 5300 Chiron Way , Emeryville , California 94608 , United States.; Barrett MP; University of Glasgow , University Place , Glasgow G12 8TA , United Kingdom.; Dranoff G; Immuno-oncology , Novartis Institutes for Biomedical Research (NIBR) , 250 Massachusetts Avenue , Cambridge , Massachusetts 02139 , United States.; Faraday CJ; Autoimmunity, Transplantation and Inflammation , NIBR , Fabrikstrasse 2 , CH-4056 Basel , Switzerland.; Gimpelewicz CR; Global Drug Development, Novartis Pharma, Forum 1, CH-4056 Basel , Switzerland.; Hailu A; School of Medicine, Addis Ababa University , P.O. Box 28017 code 1000 , Addis Ababa , Ethiopia.; Jones CL; Novartis Institute for Tropical Diseases (NITD) , 5300 Chiron Way , Emeryville , California 94608 , United States.; Kelly JM; London School of Hygiene and Tropical Medicine , Keppel Street , London WC1E 7HT , United Kingdom.; Lazdins-Helds JK; Independent Consultant, Chemic Des Tulipiers 9 , 1208 Geneva , Switzerland.; Mäser P; Swiss Tropical and Public Health Institute, Socinstrasse 57, 4501 Basel, Switzerland; University of Basel , CH 4000 Basel , Switzerland.; Mengel J; Laboratory of Clinical Immunology , Oswaldo Cruz Institute , FIOCRUZ-RJ, Av. Brasil 4365 , Cep: 21040-900 , Rio de Janeiro -RJ, Brazil.; Faculty of Medicine of Petropolis , University in Petròpolis , Av. Barao do Rio Branco 1003 , Cep: 25680-120 , Petropolis -RJ, Brazil.; Mottram JC; University of York , Wentworth Way Heslington , York YO10 5DD , United Kingdom.; Mowbray CE; Drugs for Neglected Diseases initiative, 15 Chemin Louis-Dunant , 1202 Geneva , Switzerland.; Sacks DL; National Institute of Allergy and Infectious Diseases , 4 Memorial Drive , Bethesda , Maryland 20892 , United States.; Scott P; University of Pennsylvania , 380 South University Avenue , Philadelphia , Pennsylvania 19104 , United States.; Späth GF; Institut Pasteur, 25 Rue du Docteur Roux , 75015 Paris , France.; Tarleton RL; University of Georgia , Coverdell Center, 500 DW Brooks Dr , Athens , Georgia 30602 , United States.; Spector JM; Novartis Institute for Tropical Diseases (NITD) , 5300 Chiron Way , Emeryville , California 94608 , United States.; Diagana TT; Novartis Institute for Tropical Diseases (NITD) , 5300 Chiron Way , Emeryville , California 94608 , United States. |
| Source: | ACS infectious diseases [ACS Infect Dis] 2019 Feb 08; Vol. 5 (2), pp. 152-157. Date of Electronic Publication: 2018 Dec 13. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: ACS Publications Country of Publication: United States NLM ID: 101654580 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2373-8227 (Electronic) Linking ISSN: 23738227 NLM ISO Abbreviation: ACS Infect Dis Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Washington, DC : ACS Publications, [2015]- |
| MeSH Terms: | Antiprotozoal Agents/*pharmacology ; Drug Discovery/*trends ; Euglenozoa Infections/*drug therapy ; Kinetoplastida/*drug effects; Chagas Disease/drug therapy ; Leishmaniasis/drug therapy ; Animals ; Host-Parasite Interactions ; Humans ; Immunomodulation ; Mice ; Models, Animal |
| Abstract: | Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases. |
| Grant Information: | MR/L018853/1 United Kingdom MRC_ Medical Research Council; MR/S019650/1 United Kingdom MRC_ Medical Research Council |
| Substance Nomenclature: | 0 (Antiprotozoal Agents) |
| Entry Date(s): | Date Created: 20181214 Date Completed: 20191212 Latest Revision: 20250530 |
| Update Code: | 20260130 |
| DOI: | 10.1021/acsinfecdis.8b00298 |
| PMID: | 30543391 |
| Database: | MEDLINE |
Journal Article